Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Rosa Maria Nadal"'
Autor:
Andrea B. Apolo, Amir Mortazavi, Mark N. Stein, Nicole N. Davarpanah, Rosa Maria Nadal, Howard L. Parnes, Yangmin M. Ning, Deneise C Francis, Lisa M Cordes, Marilise Anne Berniger, Seth M. Steinberg, Piyush K. Agarwal, Mohammadhadi H. Bagheri, Swati Nanda, Paul Monk, Tiffany Lancaster, Tina Moore, Rene Costello, Donald P. Bottaro, Sumanta K. Pal
Publikováno v:
Journal of Clinical Oncology. 35:4562-4562
4562 Background: We report the safety and clinical activity of the combination of CaboNivo and CaboNivoIpi in pts with mUC and other mGU tumors (NCT02496208). Methods: In this phase I trial 30 pts were treated in 4 dose levels (DL) for part 1 (CaboNi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e97fcd68a4cecb8c6798625e693cf1cd
https://doi.org/10.1200/jco.2017.35.15_suppl.4562
https://doi.org/10.1200/jco.2017.35.15_suppl.4562
Autor:
Benjamin Louis Maughan, Daniel L. Suzman, Rosa Maria Nadal, Sunakshi Bassi, Emmanuel S. Antonarakis
Publikováno v:
Journal of Clinical Oncology. 34:308-308
308 Background: Both enzalutamide and abiraterone are approved for the treatment of mCRPC, each demonstrating improved overall survival (OS) versus placebo. However, it is unclear what the optimal sequencing of these two therapies should be to maximi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ca0253346831ace404b8193c4a0d8ee
https://doi.org/10.1200/jco.2016.34.2_suppl.308
https://doi.org/10.1200/jco.2016.34.2_suppl.308